Meningioma - Revision history

Jensflorian: /* IHC */ update

2022-09-19T14:13:57Z

IHC: update

← Older revision		Revision as of 14:13, 19 September 2022
Line 370:		Line 370:
	*PR +ve (approx. 75%, expression decreases from grade I to III).		*PR +ve (approx. 75%, expression decreases from grade I to III).
	*SSTR2A +ve (approx. 95%).		*SSTR2A +ve (approx. 95%).
	*S100 variable (up to 35% cases, usually patchy).		*S100 variable (up to 35% cases, usually patchy).<ref>{{cite journal \|vauthors=Behling F, Fodi C, Skardelly M, Paulsen F, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J \|title=The prognostic role of the immunohistochemical expression of S100 in meningiomas \|journal=J Cancer Res Clin Oncol \|volume= \|issue= \|pages= \|date=July 2022 \|pmid=35838837 \|doi=10.1007/s00432-022-04186-9 \|url=}}</ref>
	*SOX10 -ve.		*SOX10 -ve.
	*GFAP -ve.		*GFAP -ve.
	*CD34 usu. -ve (approx 8% cases positive).		*CD34 usu. -ve (approx 8% cases positive).
			*CD13 +ve.<ref>{{cite journal \|vauthors=Marletta S, Luchini C, Sperandio N, Torresani E, Sorio A, Girolami I, Scarpa A, Eccher A, Ghimenton C \|title=CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications \|journal=Virchows Arch \|volume=480 \|issue=6 \|pages=1223–1230 \|date=June 2022 \|pmid=35212813 \|pmc=9184408 \|doi=10.1007/s00428-022-03304-9 \|url=}}</ref>
	*Other CKs usually -ve (approx 6% cases positive, mostly secretory meningiomas).		*Other CKs usually -ve (approx 6% cases positive, mostly secretory meningiomas).

Jensflorian: /* Molecular */ update

2022-09-19T14:06:49Z

Molecular: update

← Older revision		Revision as of 14:06, 19 September 2022
Line 377:		Line 377:

	==Molecular==		==Molecular==
	Non-syndromal meningiomas may show AKT1/TRAF7, SMO, KLF4/TRAF7, and PIK3CA mutations.<ref>{{Cite journal \| last1 = Clark \| first1 = VE. \| last2 = Erson-Omay \| first2 = EZ. \| last3 = Serin \| first3 = A. \| last4 = Yin \| first4 = J. \| last5 = Cotney \| first5 = J. \| last6 = Ozduman \| first6 = K. \| last7 = Avşar \| first7 = T. \| last8 = Li \| first8 = J. \| last9 = Murray \| first9 = PB. \| title = Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. \| journal = Science \| volume = 339 \| issue = 6123 \| pages = 1077-80 \| month = Mar \| year = 2013 \| doi = 10.1126/science.1233009 \| PMID = 23348505 }}</ref>		Non-syndromal meningiomas may show AKT1/TRAF7, SMO, KLF4/TRAF7, and PIK3CA mutations (1/3 of cases).<ref>{{Cite journal \| last1 = Clark \| first1 = VE. \| last2 = Erson-Omay \| first2 = EZ. \| last3 = Serin \| first3 = A. \| last4 = Yin \| first4 = J. \| last5 = Cotney \| first5 = J. \| last6 = Ozduman \| first6 = K. \| last7 = Avşar \| first7 = T. \| last8 = Li \| first8 = J. \| last9 = Murray \| first9 = PB. \| title = Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. \| journal = Science \| volume = 339 \| issue = 6123 \| pages = 1077-80 \| month = Mar \| year = 2013 \| doi = 10.1126/science.1233009 \| PMID = 23348505 }}</ref>
			*AKT/TRAF7 mutations are usually basal and associated with meningothelial histology.
			*KLF4/TRAF7 mutations are highly specific for secretory histology.
			*TRAF7 mutations are the first step and occur thorughout the WD40 domain. <ref>{{cite journal \|vauthors=Dogan H, Blume C, Patel A, Jungwirth G, Sogerer L, Ratliff M, Ketter R, Herold-Mende C, Jones DTW, Wick W, Vollmuth P, Zweckberger K, Reuss D, von Deimling A, Sahm F \|title=Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas \|journal=Acta Neuropathol \|volume=144 \|issue=4 \|pages=799–802 \|date=October 2022 \|pmid=35984495 \|doi=10.1007/s00401-022-02485-6 \|url=}}</ref>

			Intraventricular meningiomas have NF2 mutations.
			<ref>{{cite journal \|vauthors=Jungwirth G, Warta R, Beynon C, Sahm F, von Deimling A, Unterberg A, Herold-Mende C, Jungk C \|title=Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT \|journal=Acta Neuropathol Commun \|volume=7 \|issue=1 \|pages=140 \|date=August 2019 \|pmid=31470906 \|pmc=6716845 \|doi=10.1186/s40478-019-0793-4 \|url=}}</ref>

	Several inherited diseases are associated with meningiomas:		Several inherited diseases are associated with meningiomas:

Jensflorian: /* Molecular */ Update on pediatric meningioma

2019-11-20T14:29:20Z

Molecular: Update on pediatric meningioma

← Older revision		Revision as of 14:29, 20 November 2019
Line 377:		Line 377:

	==Molecular==		==Molecular==
	Non-syndromal meningiomas may show SMO and ~~AKT~~ mutations.<ref>{{Cite journal \| last1 = Clark \| first1 = VE. \| last2 = Erson-Omay \| first2 = EZ. \| last3 = Serin \| first3 = A. \| last4 = Yin \| first4 = J. \| last5 = Cotney \| first5 = J. \| last6 = Ozduman \| first6 = K. \| last7 = Avşar \| first7 = T. \| last8 = Li \| first8 = J. \| last9 = Murray \| first9 = PB. \| title = Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. \| journal = Science \| volume = 339 \| issue = 6123 \| pages = 1077-80 \| month = Mar \| year = 2013 \| doi = 10.1126/science.1233009 \| PMID = 23348505 }}</ref>		Non-syndromal meningiomas may show AKT1/TRAF7, SMO, KLF4/TRAF7, and PIK3CA mutations.<ref>{{Cite journal \| last1 = Clark \| first1 = VE. \| last2 = Erson-Omay \| first2 = EZ. \| last3 = Serin \| first3 = A. \| last4 = Yin \| first4 = J. \| last5 = Cotney \| first5 = J. \| last6 = Ozduman \| first6 = K. \| last7 = Avşar \| first7 = T. \| last8 = Li \| first8 = J. \| last9 = Murray \| first9 = PB. \| title = Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. \| journal = Science \| volume = 339 \| issue = 6123 \| pages = 1077-80 \| month = Mar \| year = 2013 \| doi = 10.1126/science.1233009 \| PMID = 23348505 }}</ref>

	Several inherited diseases are associated with meningiomas:		Several inherited diseases are associated with meningiomas:
	*[[Neurofibromatosis]] type II<ref>{{Cite journal \| last1 = Fontaine \| first1 = B. \| last2 = Rouleau \| first2 = GA. \| last3 = Seizinger \| first3 = BR. \| last4 = Menon \| first4 = AG. \| last5 = Jewell \| first5 = AF. \| last6 = Martuza \| first6 = RL. \| last7 = Gusella \| first7 = JF. \| title = Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma). \| journal = Ann N Y Acad Sci \| volume = 615 \| issue = \| pages = 338-43 \| month = \| year = 1991 \| doi = \| PMID = 2039155 }}</ref>		*[[Neurofibromatosis]] type II<ref>{{Cite journal \| last1 = Fontaine \| first1 = B. \| last2 = Rouleau \| first2 = GA. \| last3 = Seizinger \| first3 = BR. \| last4 = Menon \| first4 = AG. \| last5 = Jewell \| first5 = AF. \| last6 = Martuza \| first6 = RL. \| last7 = Gusella \| first7 = JF. \| title = Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma). \| journal = Ann N Y Acad Sci \| volume = 615 \| issue = \| pages = 338-43 \| month = \| year = 1991 \| doi = \| PMID = 2039155 }}</ref>
	*Germline SMARCE1 and SMARCB1 mutations<ref>{{Cite journal \| last1 = Smith \| first1 = MJ. \| last2 = O'Sullivan \| first2 = J. \| last3 = Bhaskar \| first3 = SS. \| last4 = Hadfield \| first4 = KD. \| last5 = Poke \| first5 = G. \| last6 = Caird \| first6 = J. \| last7 = Sharif \| first7 = S. \| last8 = Eccles \| first8 = D. \| last9 = Fitzpatrick \| first9 = D. \| title = Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. \| journal = Nat Genet \| volume = 45 \| issue = 3 \| pages = 295-8 \| month = Mar \| year = 2013 \| doi = 10.1038/ng.2552 \| PMID = 23377182 }}</ref><ref>{{Cite journal \| last1 = van den Munckhof \| first1 = P. \| last2 = Christiaans \| first2 = I. \| last3 = Kenter \| first3 = SB. \| last4 = Baas \| first4 = F. \| last5 = Hulsebos \| first5 = TJ. \| title = Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. \| journal = Neurogenetics \| volume = 13 \| issue = 1 \| pages = 1-7 \| month = Feb \| year = 2012 \| doi = 10.1007/s10048-011-0300-y \| PMID = 22038540 }}</ref>		*Germline SMARCE1 and SMARCB1 mutations<ref>{{Cite journal \| last1 = Smith \| first1 = MJ. \| last2 = O'Sullivan \| first2 = J. \| last3 = Bhaskar \| first3 = SS. \| last4 = Hadfield \| first4 = KD. \| last5 = Poke \| first5 = G. \| last6 = Caird \| first6 = J. \| last7 = Sharif \| first7 = S. \| last8 = Eccles \| first8 = D. \| last9 = Fitzpatrick \| first9 = D. \| title = Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. \| journal = Nat Genet \| volume = 45 \| issue = 3 \| pages = 295-8 \| month = Mar \| year = 2013 \| doi = 10.1038/ng.2552 \| PMID = 23377182 }}</ref><ref>{{Cite journal \| last1 = van den Munckhof \| first1 = P. \| last2 = Christiaans \| first2 = I. \| last3 = Kenter \| first3 = SB. \| last4 = Baas \| first4 = F. \| last5 = Hulsebos \| first5 = TJ. \| title = Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. \| journal = Neurogenetics \| volume = 13 \| issue = 1 \| pages = 1-7 \| month = Feb \| year = 2012 \| doi = 10.1007/s10048-011-0300-y \| PMID = 22038540 }}</ref>
	*Loss of SUFU (SHH-Pathway)<ref>{{Cite journal \| last1 = Aavikko \| first1 = M. \| last2 = Li \| first2 = SP. \| last3 = Saarinen \| first3 = S. \| last4 = Alhopuro \| first4 = P. \| last5 = Kaasinen \| first5 = E. \| last6 = Morgunova \| first6 = E. \| last7 = Li \| first7 = Y. \| last8 = Vesanen \| first8 = K. \| last9 = Smith \| first9 = MJ. \| title = Loss of SUFU function in familial multiple meningioma. \| journal = Am J Hum Genet \| volume = 91 \| issue = 3 \| pages = 520-6 \| month = Sep \| year = 2012 \| doi = 10.1016/j.ajhg.2012.07.015 \| PMID = 22958902 }}</ref>		*Loss of SUFU (SHH-Pathway).<ref>{{Cite journal \| last1 = Aavikko \| first1 = M. \| last2 = Li \| first2 = SP. \| last3 = Saarinen \| first3 = S. \| last4 = Alhopuro \| first4 = P. \| last5 = Kaasinen \| first5 = E. \| last6 = Morgunova \| first6 = E. \| last7 = Li \| first7 = Y. \| last8 = Vesanen \| first8 = K. \| last9 = Smith \| first9 = MJ. \| title = Loss of SUFU function in familial multiple meningioma. \| journal = Am J Hum Genet \| volume = 91 \| issue = 3 \| pages = 520-6 \| month = Sep \| year = 2012 \| doi = 10.1016/j.ajhg.2012.07.015 \| PMID = 22958902 }}</ref>
			*Rare YAP1 fusions in a subset of pediatric meningioma (HIPPO pathyway).<ref>{{Cite journal \| last1 = Sievers \| first1 = P. \| last2 = Chiang \| first2 = J. \| last3 = Schrimpf \| first3 = D. \| last4 = Stichel \| first4 = D. \| last5 = Paramasivam \| first5 = N. \| last6 = Sill \| first6 = M. \| last7 = Gayden \| first7 = T. \| last8 = Casalini \| first8 = B. \| last9 = Reuss \| first9 = DE. \| title = YAP1-fusions in pediatric NF2-wildtype meningioma. \| journal = Acta Neuropathol \| volume = \| issue = \| pages = \| month = Nov \| year = 2019 \| doi = 10.1007/s00401-019-02095-9 \| PMID = 31734728 }}</ref>

	Methylation profiling distinguishes two major groups with six distinct clinically relevant methylation classes.<ref>{{Cite journal \| last1 = Sahm \| first1 = F. \| last2 = Schrimpf \| first2 = D. \| last3 = Stichel \| first3 = D. \| last4 = Jones \| first4 = DT. \| last5 = Hielscher \| first5 = T. \| last6 = Schefzyk \| first6 = S. \| last7 = Okonechnikov \| first7 = K. \| last8 = Koelsche \| first8 = C. \| last9 = Reuss \| first9 = DE. \| title = DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. \| journal = Lancet Oncol \| volume = \| issue = \| pages = \| month = Mar \| year = 2017 \| doi = 10.1016/S1470-2045(17)30155-9 \| PMID = 28314689 }}</ref>		Methylation profiling distinguishes two major groups with six distinct clinically relevant methylation classes.<ref>{{Cite journal \| last1 = Sahm \| first1 = F. \| last2 = Schrimpf \| first2 = D. \| last3 = Stichel \| first3 = D. \| last4 = Jones \| first4 = DT. \| last5 = Hielscher \| first5 = T. \| last6 = Schefzyk \| first6 = S. \| last7 = Okonechnikov \| first7 = K. \| last8 = Koelsche \| first8 = C. \| last9 = Reuss \| first9 = DE. \| title = DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. \| journal = Lancet Oncol \| volume = \| issue = \| pages = \| month = Mar \| year = 2017 \| doi = 10.1016/S1470-2045(17)30155-9 \| PMID = 28314689 }}</ref>

Jensflorian: /* Other morphological variants */ Image of rare variant added

2019-03-14T10:42:46Z

Other morphological variants: Image of rare variant added

← Older revision		Revision as of 10:42, 14 March 2019
Line 337:		Line 337:
	<gallery>		<gallery>
	File:Meningioma_Whorling_sclerosing.jpg \| Whorling-sclerosing features in meningioma (HE/jensflorian)		File:Meningioma_Whorling_sclerosing.jpg \| Whorling-sclerosing features in meningioma (HE/jensflorian)
			File:Meningioma_pseudorosettes.jpg \| Meningioma with rosette-forming features (HE/jensflorian)
	</gallery>		</gallery>

Jensflorian: /* IHC */ update

2018-12-21T07:40:31Z

IHC: update

← Older revision		Revision as of 07:40, 21 December 2018
Line 366:		Line 366:

	==IHC==		==IHC==
	*EMA +ve.<ref name=Ref_PSNP13>{{Ref PSNP\|13}}</ref>		*EMA +ve (approx. 90%).<ref name=Ref_PSNP13>{{Ref PSNP\|13}}</ref>
	*Other CKs usually -ve.		*PR +ve (approx. 75%, expression decreases from grade I to III).
			*SSTR2A +ve (approx. 95%).
			*S100 variable (up to 35% cases, usually patchy).
			*SOX10 -ve.
			*GFAP -ve.
			*CD34 usu. -ve (approx 8% cases positive).
			*Other CKs usually -ve (approx 6% cases positive, mostly secretory meningiomas).

	==Molecular==		==Molecular==

Jensflorian: /* Prognosis */ factors

2018-04-12T06:08:36Z

Prognosis: factors

← Older revision		Revision as of 06:08, 12 April 2018
Line 44:		Line 44:
	**Metastases are rare and then usu. after surgery.		**Metastases are rare and then usu. after surgery.
	*May be malignant - bad prognosis.		*May be malignant - bad prognosis.

			*Factors associated with unfavourable prognosis:
			**BAP1 mutations.<ref>{{Cite journal \| last1 = Shankar \| first1 = GM. \| last2 = Abedalthagafi \| first2 = M. \| last3 = Vaubel \| first3 = RA. \| last4 = Merrill \| first4 = PH. \| last5 = Nayyar \| first5 = N. \| last6 = Gill \| first6 = CM. \| last7 = Brewster \| first7 = R. \| last8 = Bi \| first8 = WL. \| last9 = Agarwalla \| first9 = PK. \| title = Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. \| journal = Neuro Oncol \| volume = 19 \| issue = 4 \| pages = 535-545 \| month = 04 \| year = 2017 \| doi = 10.1093/neuonc/now235 \| PMID = 28170043 }}</ref>
			**Presence of TERT promotor mutation.<ref>{{Cite journal \| last1 = Sahm \| first1 = F. \| last2 = Schrimpf \| first2 = D. \| last3 = Olar \| first3 = A. \| last4 = Koelsche \| first4 = C. \| last5 = Reuss \| first5 = D. \| last6 = Bissel \| first6 = J. \| last7 = Kratz \| first7 = A. \| last8 = Capper \| first8 = D. \| last9 = Schefzyk \| first9 = S. \| title = TERT Promoter Mutations and Risk of Recurrence in Meningioma. \| journal = J Natl Cancer Inst \| volume = 108 \| issue = 5 \| pages = \| month = May \| year = 2016 \| doi = 10.1093/jnci/djv377 \| PMID = 26668184 }}</ref>
			**Loss of H3K27me3.<ref>{{Cite journal \| last1 = Katz \| first1 = LM. \| last2 = Hielscher \| first2 = T. \| last3 = Liechty \| first3 = B. \| last4 = Silverman \| first4 = J. \| last5 = Zagzag \| first5 = D. \| last6 = Sen \| first6 = R. \| last7 = Wu \| first7 = P. \| last8 = Golfinos \| first8 = JG. \| last9 = Reuss \| first9 = D. \| title = Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. \| journal = Acta Neuropathol \| volume = \| issue = \| pages = \| month = Apr \| year = 2018 \| doi = 10.1007/s00401-018-1844-9 \| PMID = 29627952 }}</ref>

	===Genetics===		===Genetics===

Jensflorian: /* Metaplastic meningioma */ images added

2017-04-27T08:46:30Z

Metaplastic meningioma: images added

← Older revision		Revision as of 08:46, 27 April 2017
Line 239:		Line 239:

	=====Metaplastic meningioma=====		=====Metaplastic meningioma=====
	*~~Much talked about~~..~~. but very rare~~.		*No clinical significance.
			*Probably do not represent true metaplasia in all cases.
			*Clincal information is rquired to distinguish between bone invasion and meningiomas with bone formation.

	Microscopic:		Microscopic:
	*Cartilage or bone formation.		*Cartilage or bone formation.
			*Myxoid or xanthomatous changes.

			<gallery>
			File:Metaplastic_osseous_meningioma.jpg \| Ossified meningioma, HE stain. (WC/jensflorian)
			File:Metaplastic_xanthomatous_meningioma.jpg \| Metaplastic meningioma with xanthomatous changes. (WC/jensflorian)
			</gallery>

	====Grade II====		====Grade II====

Jensflorian: /* Prognosis */ spread + metastasis

2017-04-27T08:23:48Z

Prognosis: spread + metastasis

← Older revision		Revision as of 08:23, 27 April 2017
Line 41:		Line 41:
	===Prognosis===		===Prognosis===
	*Most are benign - usu. a good prognosis.		*Most are benign - usu. a good prognosis.
	**May be malignant - bad prognosis.		**Even benign tumors may show extensive local spread - considerable morbidity and mortality.
			**Metastases are rare and then usu. after surgery.
			*May be malignant - bad prognosis.

	===Genetics===		===Genetics===

Jensflorian: /* Molecular */ methylation groups

2017-04-27T08:18:46Z

Molecular: methylation groups

← Older revision		Revision as of 08:18, 27 April 2017
Line 361:		Line 361:
	*Germline SMARCE1 and SMARCB1 mutations<ref>{{Cite journal \| last1 = Smith \| first1 = MJ. \| last2 = O'Sullivan \| first2 = J. \| last3 = Bhaskar \| first3 = SS. \| last4 = Hadfield \| first4 = KD. \| last5 = Poke \| first5 = G. \| last6 = Caird \| first6 = J. \| last7 = Sharif \| first7 = S. \| last8 = Eccles \| first8 = D. \| last9 = Fitzpatrick \| first9 = D. \| title = Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. \| journal = Nat Genet \| volume = 45 \| issue = 3 \| pages = 295-8 \| month = Mar \| year = 2013 \| doi = 10.1038/ng.2552 \| PMID = 23377182 }}</ref><ref>{{Cite journal \| last1 = van den Munckhof \| first1 = P. \| last2 = Christiaans \| first2 = I. \| last3 = Kenter \| first3 = SB. \| last4 = Baas \| first4 = F. \| last5 = Hulsebos \| first5 = TJ. \| title = Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. \| journal = Neurogenetics \| volume = 13 \| issue = 1 \| pages = 1-7 \| month = Feb \| year = 2012 \| doi = 10.1007/s10048-011-0300-y \| PMID = 22038540 }}</ref>		*Germline SMARCE1 and SMARCB1 mutations<ref>{{Cite journal \| last1 = Smith \| first1 = MJ. \| last2 = O'Sullivan \| first2 = J. \| last3 = Bhaskar \| first3 = SS. \| last4 = Hadfield \| first4 = KD. \| last5 = Poke \| first5 = G. \| last6 = Caird \| first6 = J. \| last7 = Sharif \| first7 = S. \| last8 = Eccles \| first8 = D. \| last9 = Fitzpatrick \| first9 = D. \| title = Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. \| journal = Nat Genet \| volume = 45 \| issue = 3 \| pages = 295-8 \| month = Mar \| year = 2013 \| doi = 10.1038/ng.2552 \| PMID = 23377182 }}</ref><ref>{{Cite journal \| last1 = van den Munckhof \| first1 = P. \| last2 = Christiaans \| first2 = I. \| last3 = Kenter \| first3 = SB. \| last4 = Baas \| first4 = F. \| last5 = Hulsebos \| first5 = TJ. \| title = Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. \| journal = Neurogenetics \| volume = 13 \| issue = 1 \| pages = 1-7 \| month = Feb \| year = 2012 \| doi = 10.1007/s10048-011-0300-y \| PMID = 22038540 }}</ref>
	*Loss of SUFU (SHH-Pathway)<ref>{{Cite journal \| last1 = Aavikko \| first1 = M. \| last2 = Li \| first2 = SP. \| last3 = Saarinen \| first3 = S. \| last4 = Alhopuro \| first4 = P. \| last5 = Kaasinen \| first5 = E. \| last6 = Morgunova \| first6 = E. \| last7 = Li \| first7 = Y. \| last8 = Vesanen \| first8 = K. \| last9 = Smith \| first9 = MJ. \| title = Loss of SUFU function in familial multiple meningioma. \| journal = Am J Hum Genet \| volume = 91 \| issue = 3 \| pages = 520-6 \| month = Sep \| year = 2012 \| doi = 10.1016/j.ajhg.2012.07.015 \| PMID = 22958902 }}</ref>		*Loss of SUFU (SHH-Pathway)<ref>{{Cite journal \| last1 = Aavikko \| first1 = M. \| last2 = Li \| first2 = SP. \| last3 = Saarinen \| first3 = S. \| last4 = Alhopuro \| first4 = P. \| last5 = Kaasinen \| first5 = E. \| last6 = Morgunova \| first6 = E. \| last7 = Li \| first7 = Y. \| last8 = Vesanen \| first8 = K. \| last9 = Smith \| first9 = MJ. \| title = Loss of SUFU function in familial multiple meningioma. \| journal = Am J Hum Genet \| volume = 91 \| issue = 3 \| pages = 520-6 \| month = Sep \| year = 2012 \| doi = 10.1016/j.ajhg.2012.07.015 \| PMID = 22958902 }}</ref>

			Methylation profiling distinguishes two major groups with six distinct clinically relevant methylation classes.<ref>{{Cite journal \| last1 = Sahm \| first1 = F. \| last2 = Schrimpf \| first2 = D. \| last3 = Stichel \| first3 = D. \| last4 = Jones \| first4 = DT. \| last5 = Hielscher \| first5 = T. \| last6 = Schefzyk \| first6 = S. \| last7 = Okonechnikov \| first7 = K. \| last8 = Koelsche \| first8 = C. \| last9 = Reuss \| first9 = DE. \| title = DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. \| journal = Lancet Oncol \| volume = \| issue = \| pages = \| month = Mar \| year = 2017 \| doi = 10.1016/S1470-2045(17)30155-9 \| PMID = 28314689 }}</ref>



	===DDx of meningioma & IHC<ref name=pmid16393681>{{cite journal \|author=Hahn HP, Bundock EA, Hornick JL \|title=Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics \|journal=Am. J. Clin. Pathol. \|volume=125 \|issue=2 \|pages=203–8 \|year=2006 \|month=February \|pmid=16393681 \|doi=10.1309/G659-FVVB-MG7U-4RPQ \|url=http://ajcp.ascpjournals.org/content/125/2/203.full.pdf}}</ref>===		===DDx of meningioma & IHC<ref name=pmid16393681>{{cite journal \|author=Hahn HP, Bundock EA, Hornick JL \|title=Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics \|journal=Am. J. Clin. Pathol. \|volume=125 \|issue=2 \|pages=203–8 \|year=2006 \|month=February \|pmid=16393681 \|doi=10.1309/G659-FVVB-MG7U-4RPQ \|url=http://ajcp.ascpjournals.org/content/125/2/203.full.pdf}}</ref>===

Jensflorian: /* Brain invasive meningioma */ update

2017-04-27T07:50:30Z

Brain invasive meningioma: update

← Older revision		Revision as of 07:50, 27 April 2017
Line 246:		Line 246:
	*Invades the brain (irregular, tongue-like).		*Invades the brain (irregular, tongue-like).
	*Absence of leptomeningeal layer.		*Absence of leptomeningeal layer.
	*Brain invasion can be present in grade I tumors, these are then classified as "atypical".		*Brain invasion can be present in grade I tumors, these are then classified as "atypical", ie. as grade II tumors.
	*~~Recent data indicates that tumors with~~ brain invasion do not show a course similiar to grade II meningiomas.<ref>{{Cite journal \| last1 = Baumgarten \| first1 = P. \| last2 = Gessler \| first2 = F. \| last3 = Schittenhelm \| first3 = J. \| last4 = Skardelly \| first4 = M. \| last5 = Tews \| first5 = DS. \| last6 = Senft \| first6 = C. \| last7 = Dunst \| first7 = M. \| last8 = Imoehl \| first8 = L. \| last9 = Plate \| first9 = KH. \| title = Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. \| journal = Acta Neuropathol \| volume = 132 \| issue = 3 \| pages = 479-81 \| month = Sep \| year = 2016 \| doi = 10.1007/s00401-016-1598-1 \| PMID = 27464983 }}</ref>		*The prognostic significance of brain invasion is still unclear, some studies do not show a course similiar to grade II meningiomas.<ref>{{Cite journal \| last1 = Baumgarten \| first1 = P. \| last2 = Gessler \| first2 = F. \| last3 = Schittenhelm \| first3 = J. \| last4 = Skardelly \| first4 = M. \| last5 = Tews \| first5 = DS. \| last6 = Senft \| first6 = C. \| last7 = Dunst \| first7 = M. \| last8 = Imoehl \| first8 = L. \| last9 = Plate \| first9 = KH. \| title = Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. \| journal = Acta Neuropathol \| volume = 132 \| issue = 3 \| pages = 479-81 \| month = Sep \| year = 2016 \| doi = 10.1007/s00401-016-1598-1 \| PMID = 27464983 }}</ref><ref>{{Cite journal \| last1 = Brokinkel \| first1 = B. \| last2 = Hess \| first2 = K. \| last3 = Mawrin \| first3 = C. \| title = Brain invasion in Meningiomas - Clinical considerations and impact of neuropathological evaluation: A systematic Review. \| journal = Neuro Oncol \| volume = \| issue = \| pages = \| month = Apr \| year = 2017 \| doi = 10.1093/neuonc/nox071 \| PMID = 28419308 }}</ref><ref>{{Cite journal \| last1 = Pizem \| first1 = J. \| last2 = Velnar \| first2 = T. \| last3 = Prestor \| first3 = B. \| last4 = Mlakar \| first4 = J. \| last5 = Popovic \| first5 = M. \| title = Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen. \| journal = Clin Neuropathol \| volume = 33 \| issue = 5 \| pages = 354-63 \| month = \| year = \| doi = 10.5414/NP300750 \| PMID = 25034703 }}</ref>


	Images:		Images:

← Older revision		Revision as of 14:29, 20 November 2019
Line 377:		Line 377:

	==Molecular==		==Molecular==
	Non-syndromal meningiomas may show SMO and ~~AKT~~ mutations.<ref>{{Cite journal \| last1 = Clark \| first1 = VE. \| last2 = Erson-Omay \| first2 = EZ. \| last3 = Serin \| first3 = A. \| last4 = Yin \| first4 = J. \| last5 = Cotney \| first5 = J. \| last6 = Ozduman \| first6 = K. \| last7 = Avşar \| first7 = T. \| last8 = Li \| first8 = J. \| last9 = Murray \| first9 = PB. \| title = Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. \| journal = Science \| volume = 339 \| issue = 6123 \| pages = 1077-80 \| month = Mar \| year = 2013 \| doi = 10.1126/science.1233009 \| PMID = 23348505 }}</ref>		Non-syndromal meningiomas may show AKT1/TRAF7, SMO, KLF4/TRAF7, and PIK3CA mutations.<ref>{{Cite journal \| last1 = Clark \| first1 = VE. \| last2 = Erson-Omay \| first2 = EZ. \| last3 = Serin \| first3 = A. \| last4 = Yin \| first4 = J. \| last5 = Cotney \| first5 = J. \| last6 = Ozduman \| first6 = K. \| last7 = Avşar \| first7 = T. \| last8 = Li \| first8 = J. \| last9 = Murray \| first9 = PB. \| title = Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. \| journal = Science \| volume = 339 \| issue = 6123 \| pages = 1077-80 \| month = Mar \| year = 2013 \| doi = 10.1126/science.1233009 \| PMID = 23348505 }}</ref>

	Several inherited diseases are associated with meningiomas:		Several inherited diseases are associated with meningiomas:
	*[[Neurofibromatosis]] type II<ref>{{Cite journal \| last1 = Fontaine \| first1 = B. \| last2 = Rouleau \| first2 = GA. \| last3 = Seizinger \| first3 = BR. \| last4 = Menon \| first4 = AG. \| last5 = Jewell \| first5 = AF. \| last6 = Martuza \| first6 = RL. \| last7 = Gusella \| first7 = JF. \| title = Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma). \| journal = Ann N Y Acad Sci \| volume = 615 \| issue = \| pages = 338-43 \| month = \| year = 1991 \| doi = \| PMID = 2039155 }}</ref>		*[[Neurofibromatosis]] type II<ref>{{Cite journal \| last1 = Fontaine \| first1 = B. \| last2 = Rouleau \| first2 = GA. \| last3 = Seizinger \| first3 = BR. \| last4 = Menon \| first4 = AG. \| last5 = Jewell \| first5 = AF. \| last6 = Martuza \| first6 = RL. \| last7 = Gusella \| first7 = JF. \| title = Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma). \| journal = Ann N Y Acad Sci \| volume = 615 \| issue = \| pages = 338-43 \| month = \| year = 1991 \| doi = \| PMID = 2039155 }}</ref>
	*Germline SMARCE1 and SMARCB1 mutations<ref>{{Cite journal \| last1 = Smith \| first1 = MJ. \| last2 = O'Sullivan \| first2 = J. \| last3 = Bhaskar \| first3 = SS. \| last4 = Hadfield \| first4 = KD. \| last5 = Poke \| first5 = G. \| last6 = Caird \| first6 = J. \| last7 = Sharif \| first7 = S. \| last8 = Eccles \| first8 = D. \| last9 = Fitzpatrick \| first9 = D. \| title = Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. \| journal = Nat Genet \| volume = 45 \| issue = 3 \| pages = 295-8 \| month = Mar \| year = 2013 \| doi = 10.1038/ng.2552 \| PMID = 23377182 }}</ref><ref>{{Cite journal \| last1 = van den Munckhof \| first1 = P. \| last2 = Christiaans \| first2 = I. \| last3 = Kenter \| first3 = SB. \| last4 = Baas \| first4 = F. \| last5 = Hulsebos \| first5 = TJ. \| title = Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. \| journal = Neurogenetics \| volume = 13 \| issue = 1 \| pages = 1-7 \| month = Feb \| year = 2012 \| doi = 10.1007/s10048-011-0300-y \| PMID = 22038540 }}</ref>		*Germline SMARCE1 and SMARCB1 mutations<ref>{{Cite journal \| last1 = Smith \| first1 = MJ. \| last2 = O'Sullivan \| first2 = J. \| last3 = Bhaskar \| first3 = SS. \| last4 = Hadfield \| first4 = KD. \| last5 = Poke \| first5 = G. \| last6 = Caird \| first6 = J. \| last7 = Sharif \| first7 = S. \| last8 = Eccles \| first8 = D. \| last9 = Fitzpatrick \| first9 = D. \| title = Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. \| journal = Nat Genet \| volume = 45 \| issue = 3 \| pages = 295-8 \| month = Mar \| year = 2013 \| doi = 10.1038/ng.2552 \| PMID = 23377182 }}</ref><ref>{{Cite journal \| last1 = van den Munckhof \| first1 = P. \| last2 = Christiaans \| first2 = I. \| last3 = Kenter \| first3 = SB. \| last4 = Baas \| first4 = F. \| last5 = Hulsebos \| first5 = TJ. \| title = Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. \| journal = Neurogenetics \| volume = 13 \| issue = 1 \| pages = 1-7 \| month = Feb \| year = 2012 \| doi = 10.1007/s10048-011-0300-y \| PMID = 22038540 }}</ref>
	*Loss of SUFU (SHH-Pathway)<ref>{{Cite journal \| last1 = Aavikko \| first1 = M. \| last2 = Li \| first2 = SP. \| last3 = Saarinen \| first3 = S. \| last4 = Alhopuro \| first4 = P. \| last5 = Kaasinen \| first5 = E. \| last6 = Morgunova \| first6 = E. \| last7 = Li \| first7 = Y. \| last8 = Vesanen \| first8 = K. \| last9 = Smith \| first9 = MJ. \| title = Loss of SUFU function in familial multiple meningioma. \| journal = Am J Hum Genet \| volume = 91 \| issue = 3 \| pages = 520-6 \| month = Sep \| year = 2012 \| doi = 10.1016/j.ajhg.2012.07.015 \| PMID = 22958902 }}</ref>		*Loss of SUFU (SHH-Pathway).<ref>{{Cite journal \| last1 = Aavikko \| first1 = M. \| last2 = Li \| first2 = SP. \| last3 = Saarinen \| first3 = S. \| last4 = Alhopuro \| first4 = P. \| last5 = Kaasinen \| first5 = E. \| last6 = Morgunova \| first6 = E. \| last7 = Li \| first7 = Y. \| last8 = Vesanen \| first8 = K. \| last9 = Smith \| first9 = MJ. \| title = Loss of SUFU function in familial multiple meningioma. \| journal = Am J Hum Genet \| volume = 91 \| issue = 3 \| pages = 520-6 \| month = Sep \| year = 2012 \| doi = 10.1016/j.ajhg.2012.07.015 \| PMID = 22958902 }}</ref>
			*Rare YAP1 fusions in a subset of pediatric meningioma (HIPPO pathyway).<ref>{{Cite journal \| last1 = Sievers \| first1 = P. \| last2 = Chiang \| first2 = J. \| last3 = Schrimpf \| first3 = D. \| last4 = Stichel \| first4 = D. \| last5 = Paramasivam \| first5 = N. \| last6 = Sill \| first6 = M. \| last7 = Gayden \| first7 = T. \| last8 = Casalini \| first8 = B. \| last9 = Reuss \| first9 = DE. \| title = YAP1-fusions in pediatric NF2-wildtype meningioma. \| journal = Acta Neuropathol \| volume = \| issue = \| pages = \| month = Nov \| year = 2019 \| doi = 10.1007/s00401-019-02095-9 \| PMID = 31734728 }}</ref>

	Methylation profiling distinguishes two major groups with six distinct clinically relevant methylation classes.<ref>{{Cite journal \| last1 = Sahm \| first1 = F. \| last2 = Schrimpf \| first2 = D. \| last3 = Stichel \| first3 = D. \| last4 = Jones \| first4 = DT. \| last5 = Hielscher \| first5 = T. \| last6 = Schefzyk \| first6 = S. \| last7 = Okonechnikov \| first7 = K. \| last8 = Koelsche \| first8 = C. \| last9 = Reuss \| first9 = DE. \| title = DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. \| journal = Lancet Oncol \| volume = \| issue = \| pages = \| month = Mar \| year = 2017 \| doi = 10.1016/S1470-2045(17)30155-9 \| PMID = 28314689 }}</ref>		Methylation profiling distinguishes two major groups with six distinct clinically relevant methylation classes.<ref>{{Cite journal \| last1 = Sahm \| first1 = F. \| last2 = Schrimpf \| first2 = D. \| last3 = Stichel \| first3 = D. \| last4 = Jones \| first4 = DT. \| last5 = Hielscher \| first5 = T. \| last6 = Schefzyk \| first6 = S. \| last7 = Okonechnikov \| first7 = K. \| last8 = Koelsche \| first8 = C. \| last9 = Reuss \| first9 = DE. \| title = DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. \| journal = Lancet Oncol \| volume = \| issue = \| pages = \| month = Mar \| year = 2017 \| doi = 10.1016/S1470-2045(17)30155-9 \| PMID = 28314689 }}</ref>

← Older revision		Revision as of 08:18, 27 April 2017
Line 361:		Line 361:
	*Germline SMARCE1 and SMARCB1 mutations<ref>{{Cite journal \| last1 = Smith \| first1 = MJ. \| last2 = O'Sullivan \| first2 = J. \| last3 = Bhaskar \| first3 = SS. \| last4 = Hadfield \| first4 = KD. \| last5 = Poke \| first5 = G. \| last6 = Caird \| first6 = J. \| last7 = Sharif \| first7 = S. \| last8 = Eccles \| first8 = D. \| last9 = Fitzpatrick \| first9 = D. \| title = Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. \| journal = Nat Genet \| volume = 45 \| issue = 3 \| pages = 295-8 \| month = Mar \| year = 2013 \| doi = 10.1038/ng.2552 \| PMID = 23377182 }}</ref><ref>{{Cite journal \| last1 = van den Munckhof \| first1 = P. \| last2 = Christiaans \| first2 = I. \| last3 = Kenter \| first3 = SB. \| last4 = Baas \| first4 = F. \| last5 = Hulsebos \| first5 = TJ. \| title = Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. \| journal = Neurogenetics \| volume = 13 \| issue = 1 \| pages = 1-7 \| month = Feb \| year = 2012 \| doi = 10.1007/s10048-011-0300-y \| PMID = 22038540 }}</ref>		*Germline SMARCE1 and SMARCB1 mutations<ref>{{Cite journal \| last1 = Smith \| first1 = MJ. \| last2 = O'Sullivan \| first2 = J. \| last3 = Bhaskar \| first3 = SS. \| last4 = Hadfield \| first4 = KD. \| last5 = Poke \| first5 = G. \| last6 = Caird \| first6 = J. \| last7 = Sharif \| first7 = S. \| last8 = Eccles \| first8 = D. \| last9 = Fitzpatrick \| first9 = D. \| title = Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. \| journal = Nat Genet \| volume = 45 \| issue = 3 \| pages = 295-8 \| month = Mar \| year = 2013 \| doi = 10.1038/ng.2552 \| PMID = 23377182 }}</ref><ref>{{Cite journal \| last1 = van den Munckhof \| first1 = P. \| last2 = Christiaans \| first2 = I. \| last3 = Kenter \| first3 = SB. \| last4 = Baas \| first4 = F. \| last5 = Hulsebos \| first5 = TJ. \| title = Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. \| journal = Neurogenetics \| volume = 13 \| issue = 1 \| pages = 1-7 \| month = Feb \| year = 2012 \| doi = 10.1007/s10048-011-0300-y \| PMID = 22038540 }}</ref>
	*Loss of SUFU (SHH-Pathway)<ref>{{Cite journal \| last1 = Aavikko \| first1 = M. \| last2 = Li \| first2 = SP. \| last3 = Saarinen \| first3 = S. \| last4 = Alhopuro \| first4 = P. \| last5 = Kaasinen \| first5 = E. \| last6 = Morgunova \| first6 = E. \| last7 = Li \| first7 = Y. \| last8 = Vesanen \| first8 = K. \| last9 = Smith \| first9 = MJ. \| title = Loss of SUFU function in familial multiple meningioma. \| journal = Am J Hum Genet \| volume = 91 \| issue = 3 \| pages = 520-6 \| month = Sep \| year = 2012 \| doi = 10.1016/j.ajhg.2012.07.015 \| PMID = 22958902 }}</ref>		*Loss of SUFU (SHH-Pathway)<ref>{{Cite journal \| last1 = Aavikko \| first1 = M. \| last2 = Li \| first2 = SP. \| last3 = Saarinen \| first3 = S. \| last4 = Alhopuro \| first4 = P. \| last5 = Kaasinen \| first5 = E. \| last6 = Morgunova \| first6 = E. \| last7 = Li \| first7 = Y. \| last8 = Vesanen \| first8 = K. \| last9 = Smith \| first9 = MJ. \| title = Loss of SUFU function in familial multiple meningioma. \| journal = Am J Hum Genet \| volume = 91 \| issue = 3 \| pages = 520-6 \| month = Sep \| year = 2012 \| doi = 10.1016/j.ajhg.2012.07.015 \| PMID = 22958902 }}</ref>

			Methylation profiling distinguishes two major groups with six distinct clinically relevant methylation classes.<ref>{{Cite journal \| last1 = Sahm \| first1 = F. \| last2 = Schrimpf \| first2 = D. \| last3 = Stichel \| first3 = D. \| last4 = Jones \| first4 = DT. \| last5 = Hielscher \| first5 = T. \| last6 = Schefzyk \| first6 = S. \| last7 = Okonechnikov \| first7 = K. \| last8 = Koelsche \| first8 = C. \| last9 = Reuss \| first9 = DE. \| title = DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. \| journal = Lancet Oncol \| volume = \| issue = \| pages = \| month = Mar \| year = 2017 \| doi = 10.1016/S1470-2045(17)30155-9 \| PMID = 28314689 }}</ref>



	===DDx of meningioma & IHC<ref name=pmid16393681>{{cite journal \|author=Hahn HP, Bundock EA, Hornick JL \|title=Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics \|journal=Am. J. Clin. Pathol. \|volume=125 \|issue=2 \|pages=203–8 \|year=2006 \|month=February \|pmid=16393681 \|doi=10.1309/G659-FVVB-MG7U-4RPQ \|url=http://ajcp.ascpjournals.org/content/125/2/203.full.pdf}}</ref>===		===DDx of meningioma & IHC<ref name=pmid16393681>{{cite journal \|author=Hahn HP, Bundock EA, Hornick JL \|title=Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics \|journal=Am. J. Clin. Pathol. \|volume=125 \|issue=2 \|pages=203–8 \|year=2006 \|month=February \|pmid=16393681 \|doi=10.1309/G659-FVVB-MG7U-4RPQ \|url=http://ajcp.ascpjournals.org/content/125/2/203.full.pdf}}</ref>===